首页 › 三阴性乳腺癌 › 宾夕法尼亚州 › Pittsburgh
Pittsburgh PA 三阴性乳腺癌临床试验
11项针对 三阴性乳腺癌的研究正在 Pittsburgh及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- University of Pittsburgh Medical Center, Pittsburgh
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
招募中
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
招募中1 期
- UPMC, Pittsburgh
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
招募中2 期
- UPMC Hillman Cancer Center, Pittsburgh
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
招募中3 期
- UPMC Magee-Womens Hospital, Pittsburgh
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- UPMC Hillman Cancer Center, Pittsburgh
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
招募中1/2 期
- Research Site, Pittsburgh
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
招募中2/3 期
- Local Institution - 0360, Pittsburgh
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- Allegheny Health Network, Pittsburgh
ctDNA Positive Patients Diagnosed With cT1bN0 and cT1cN0 TNBC
招募中观察性研究
- UPMC Hillman Cancer, Pittsburgh
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
招募中1/2 期
- University of Pittsburgh Medical Center, Pittsburgh
其他城市的 三阴性乳腺癌试验
- Houston, TX42 项研究
- New York City, NY31 项研究
- Nashville, TN28 项研究
- Los Angeles, CA27 项研究
- Boston, MA26 项研究
- San Antonio, TX23 项研究
- St. Louis, MO21 项研究
- Arlington, VA20 项研究
- Atlanta, GA20 项研究
- Dallas, TX18 项研究
- Chicago, IL16 项研究
- Columbus, OH16 项研究
Pittsburgh的其他研究
- 非小细胞肺癌48 项研究
- 癌症（所有类型）41 项研究
- 乳腺癌39 项研究
- 结直肠癌32 项研究
- 转移性癌症31 项研究
- 黑色素瘤31 项研究
- 卵巢癌30 项研究
- 子宫内膜癌23 项研究
- 前列腺癌23 项研究
- 肺癌23 项研究
- 头颈鳞状细胞癌22 项研究
- 卒中22 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。